Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

Jorge E. Cortes, Dan Jones, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Charles Koller, Gautam Borthakur, Brenda Walker, Weiqiang Zhao, Jianqin Shan, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods: Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results: Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade ≥ 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion: Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.

Original languageEnglish (US)
Pages (from-to)389-404
Number of pages16
JournalJournal of Clinical Oncology
Volume28
Issue number3
DOIs
StatePublished - Jan 20 2010
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Therapeutics
Dasatinib
Neutropenia
Disease-Free Survival
Survival Rate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. / Cortes, Jorge E.; Jones, Dan; O'Brien, Susan; Jabbour, Elias; Ravandi, Farhad; Koller, Charles; Borthakur, Gautam; Walker, Brenda; Zhao, Weiqiang; Shan, Jianqin; Kantarjian, Hagop.

In: Journal of Clinical Oncology, Vol. 28, No. 3, 20.01.2010, p. 389-404.

Research output: Contribution to journalArticle

Cortes, JE, Jones, D, O'Brien, S, Jabbour, E, Ravandi, F, Koller, C, Borthakur, G, Walker, B, Zhao, W, Shan, J & Kantarjian, H 2010, 'Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia', Journal of Clinical Oncology, vol. 28, no. 3, pp. 389-404. https://doi.org/10.1200/JCO.2009.25.4920
Cortes, Jorge E. ; Jones, Dan ; O'Brien, Susan ; Jabbour, Elias ; Ravandi, Farhad ; Koller, Charles ; Borthakur, Gautam ; Walker, Brenda ; Zhao, Weiqiang ; Shan, Jianqin ; Kantarjian, Hagop. / Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 3. pp. 389-404.
@article{4b7a36a1c77f40b59a1cc40b2e3eade2,
title = "Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia",
abstract = "Purpose: Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods: Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results: Among 50 patients observed for at least 3 months, 49 patients (98{\%}) achieved a complete cytogenetic response (CCyR), and 41 patients (82{\%}) achieved a major molecular response (MMR). Responses occurred rapidly, with 94{\%} of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88{\%}, and all patients are alive after a median follow-up time of 24 months. Grade ≥ 3 neutropenia and thrombocytopenia occurred in 21{\%} and 10{\%} of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion: Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.",
author = "Cortes, {Jorge E.} and Dan Jones and Susan O'Brien and Elias Jabbour and Farhad Ravandi and Charles Koller and Gautam Borthakur and Brenda Walker and Weiqiang Zhao and Jianqin Shan and Hagop Kantarjian",
year = "2010",
month = "1",
day = "20",
doi = "10.1200/JCO.2009.25.4920",
language = "English (US)",
volume = "28",
pages = "389--404",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

AU - Cortes, Jorge E.

AU - Jones, Dan

AU - O'Brien, Susan

AU - Jabbour, Elias

AU - Ravandi, Farhad

AU - Koller, Charles

AU - Borthakur, Gautam

AU - Walker, Brenda

AU - Zhao, Weiqiang

AU - Shan, Jianqin

AU - Kantarjian, Hagop

PY - 2010/1/20

Y1 - 2010/1/20

N2 - Purpose: Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods: Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results: Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade ≥ 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion: Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.

AB - Purpose: Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods: Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results: Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade ≥ 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion: Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.

UR - http://www.scopus.com/inward/record.url?scp=75749129911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749129911&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.4920

DO - 10.1200/JCO.2009.25.4920

M3 - Article

C2 - 20008620

AN - SCOPUS:75749129911

VL - 28

SP - 389

EP - 404

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -